XOMA Royalty (NASDAQ:XOMA) Sees Unusually-High Trading Volume – Time to Buy?

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) saw strong trading volume on Monday . 342,730 shares changed hands during mid-day trading, an increase of 16% from the previous session’s volume of 295,767 shares.The stock last traded at $43.05 and had previously closed at $44.22.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on XOMA shares. Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings upgraded XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 29th. Zacks Research upgraded XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. HC Wainwright lowered shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price objective for the company. in a research note on Thursday, April 30th. Finally, Benchmark cut shares of XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd. One analyst has rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, XOMA Royalty currently has a consensus rating of “Hold” and a consensus price target of $53.75.

XOMA Royalty Trading Down 2.0%

The company’s 50 day simple moving average is $42.08 and its 200-day simple moving average is $33.93. The firm has a market cap of $493.51 million, a P/E ratio of 25.07 and a beta of 0.86. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.96.

XOMA Royalty (NASDAQ:XOMA) last released its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. The business had revenue of $12.32 million for the quarter, compared to the consensus estimate of $13.91 million. As a group, research analysts predict that XOMA Royalty Corporation will post 0.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On XOMA Royalty

Several hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its stake in XOMA Royalty by 207.7% in the first quarter. Dimensional Fund Advisors LP now owns 133,360 shares of the biotechnology company’s stock worth $4,182,000 after purchasing an additional 90,025 shares during the period. Bank of New York Mellon Corp lifted its position in shares of XOMA Royalty by 9.7% during the first quarter. Bank of New York Mellon Corp now owns 74,984 shares of the biotechnology company’s stock worth $2,352,000 after purchasing an additional 6,600 shares during the last quarter. Opaleye Management Inc. boosted its stake in shares of XOMA Royalty by 14.7% during the fourth quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock valued at $7,780,000 after purchasing an additional 37,503 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of XOMA Royalty during the fourth quarter valued at $237,000. Finally, Panagora Asset Management Inc. grew its holdings in shares of XOMA Royalty by 24.2% in the fourth quarter. Panagora Asset Management Inc. now owns 21,229 shares of the biotechnology company’s stock worth $564,000 after purchasing an additional 4,135 shares during the last quarter. Institutional investors own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.